Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E White

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1989
Functional and psychosocial effects of multimodality limb-sparing therapy in patients with soft tissue sarcomasA E Chang, S M Steinberg, M Culnane, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 1991
Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcomaS F Stinson, T F DeLaney, J Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1992
Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I studyM G Sanda, J C Yang, S L Topalian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim reportJ C Yang, S L Topalian, D Parkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapyB A Pockaj, J C Yang, M T Lotze, et al.
Journal of the National Cancer Institute|August 3, 1994
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2S A Rosenberg, J R Yannelli, J C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinomaA S Guleria, J C Yang, S L Topalian, et al.
Oncogene|March 23, 2010
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancerS M Pontier, L Huck, D E White, et al.
Journal of the National Cancer Institute|December 23, 1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensS A Rosenberg, Y Zhai, J C Yang, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1989
Functional and psychosocial effects of multimodality limb-sparing therapy in patients with soft tissue sarcomasA E Chang, S M Steinberg, M Culnane, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 1991
Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcomaS F Stinson, T F DeLaney, J Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1992
Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I studyM G Sanda, J C Yang, S L Topalian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim reportJ C Yang, S L Topalian, D Parkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapyB A Pockaj, J C Yang, M T Lotze, et al.
Journal of the National Cancer Institute|August 3, 1994
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2S A Rosenberg, J R Yannelli, J C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinomaA S Guleria, J C Yang, S L Topalian, et al.
Oncogene|March 23, 2010
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancerS M Pontier, L Huck, D E White, et al.
Journal of the National Cancer Institute|December 23, 1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensS A Rosenberg, Y Zhai, J C Yang, et al.
Pageof 7